文献类型：期刊文献

英文题名：Combination therapy with p53-MDM2 binding inhibitors for malignancies

作者：Jin, Zegao[1];Shen, Jianfeng[2];He, Jingyao[1];Hu, Chunqi[1]

机构：[1]Shaoxing Univ, Chem & Chem Engn Inst, Dept Pharmacol, Shaoxing 312000, Zhejiang, Peoples R China;[2]Zhejiang Zhenyuan Pharmaceut, Shaoxing 312000, Zhejiang, Peoples R China

年份：2015

卷号：24

期号：4

起止页码：1369

外文期刊名：MEDICINAL CHEMISTRY RESEARCH

收录：SCI-EXPANDED(收录号：WOS:000350365100002)、、Scopus(收录号：2-s2.0-84923857022)、WOS

基金：This study was financially supported by Zhejiang Provincial Natural Science Foundation of China under Grant No. LQ13H300001.

语种：英文

外文关键词：Nutlin-3; MIs; p53-MDM2 binding inhibitors; Anti-cancer; Combination therapy

外文摘要：p53 is a powerful tumor suppressor, and p53-MDM2 protein-protein interaction has been considered as an attractive cancer therapeutic target. More recently developed small molecules exert their effects by interrupting the p53-MDM2 binding and enhancing the anti-proliferative activities of p53. Small molecules such as Nutlin, MI-63, MI-219, and MI-319 that can activate p53 have shown their anti-tumor effects in different types of malignancies. Drug combinations between p53-MDM2 binding inhibitors with the other anti-proliferative small molecules may allow reduction in the amount of single component with a lower incidence of side effects or better therapeutic effects. In this current review, we present the recent achievements in combination applications between p53-MDM2 binding inhibitors with other small molecules in malignancies. In addition, we discuss how this combination holds promise as a therapeutic strategy for recent and future novel therapies in these diseases.